Documents

Filter documents Clear search

pdf icon

FSRH CEU Statement on Nexplanon® Insertion Site 15 January 2020

File size: 327kb | Date: 15 January 2020 | Clinical Statements - PDF

This CEU Statement provides guidance to healthcare professionals in response to a letter circulated by MSD (manufacturer of Nexplanon®) to healthcare professionals in the UK about updated guidance regarding the recommended Nexplanon® insertion site.

pdf icon

FSRH CEU statement Levosert 6 year license for contraception - Feb 2021

File size: 378kb | Date: 8 February 2021 | Clinical Statements - PDF

This statement notes that the Levosert® 52mg LNG-IUS has been licensed for contraceptive use for 6 years. Levosert remains licensed for 5 years for management of heavy menstrual bleeding and is not licensed for endometrial protection as part of HRT.

pdf icon

FSRH CEU Statement: Response to recently published “Bridge-It” study by Cameron, et al - November 2020

File size: 209kb | Date: 23 November 2020 | Clinical Statements - PDF

The FSRH CEU summarizes and comments on the Cameron, et al “Bridge-It” study, which found that women receiving levonorgestrel emergency contraception from a pharmacy are more likely to be using effective ongoing contraception if they are given a three-month supply of progestogen-only pill and facilitated access to local SRH services.

pdf icon

FSRH CEU Statement: Response to Recent Publication Regarding Banh, et al - November 2020

File size: 233kb | Date: 17 November 2020 | Clinical Statements - PDF

“The effects on ovarian activity of delaying versus immediately restarting combined oral contraception after missing three pills and taking ulipristal acetate 30 mg” The journal Contraception recently published a study investigating timing of combined oral contraceptive pill (COC) restart after missed pills and use of ulipristal acetate emergency contraception (UPA-EC). The FSRH CEU responds to this study and advises where guidance does—and does not—change.

pdf icon

FSRH CEU recommendation on extended use of the etonogestrel implant and 52mg levonorgestrel-releasing intrauterine system during COVID restrictions

File size: 396kb | Date: 20 March 2020 | Clinical Statements - PDF

At present, to reduce risk of coronavirus transmission, non-essential face-to-face contact with healthcare providers is being minimised where possible. Replacement procedures for long-acting reversible contraceptive (LARC) devices that have recently expired are non-essential. This FSRH CEU statement provides recommendation on extended use of the etonogestrel implant and 52mg levonorgestrel-releasing intrauterine system during COVID restrictions.